{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:11:36Z","timestamp":1789593096169,"version":"build-2803163510"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>The renin-angiotensin-aldosterone system (RAAS) is essential to cardiovascular homeostasis, particularly in heart failure (HF) and cardiogenic shock states. Relative angiotensin II depletion is a potential mechanism for postoperative hypotension and may be potentiated by pre-existing HF. The availability of exogenous AT2 allows for tailored vasoplegia management in a state of RAAS dysregulation. This prospective, single-institution pilot study aimed to characterize the expected reduction in angiotensin II (AT2) and angiotensin I (AT1) levels following cardiopulmonary bypass (CPB) in patients with and without chronic systolic HF, with enrollment of 10 patients in each arm. Preoperative AT2 and AT1 levels were significantly higher in patients with HF and remained so following cardiac surgery. A lower postoperative AT2 correlated with lower mean arterial pressure and a trend toward higher pressor requirements in HF patients only. No association was seen in HF or non-HF patients between CPB time and the change in AT1, AT2, or their ratio. Taken together, this pilot study suggests a role for characterizing RAAS function in patients with HF undergoing cardiac surgery for prediction and treatment of postcardiotomy vasoplegia.<\/jats:p>","DOI":"10.1097\/mat.0000000000002854","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:00:22Z","timestamp":1789592422000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Plasma Angiotensin Levels and Postoperative Hypotension in Patients With and Without Chronic Heart Failure Undergoing Cardiac Surgery"],"prefix":"10.1097","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0854-7241","authenticated-orcid":false,"given":"Laura","family":"DiChiacchio","sequence":"first","affiliation":[{"name":"Department of Cardiac Surgery, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Hamouche","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, University of Utah Hospital, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5011-3036","authenticated-orcid":false,"given":"Eleni","family":"Maneta","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, University of Utah Hospital, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Forest","family":"Riekhof","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, University of Utah Hospital, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavros G.","family":"Drakos","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, University of Utah Hospital, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig H.","family":"Selzman","sequence":"additional","affiliation":[{"name":"Division of Cardiothoracic Surgery, Department of Surgery, University of Utah Hospital, Salt Lake City, Utah."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Hanff","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, University of Utah Hospital, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"issue":"Suppl 3","key":"R1-20260916","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/00005344-199000153-00001","article-title":"The renin-angiotensin system: Importance in physiology and pathology.","volume":"15","author":"Ferrario","year":"1990","journal-title":"J Cardiovasc Pharmacol"},{"key":"R2-20260916","doi-asserted-by":"crossref","first-page":"102411","DOI":"10.1016\/j.cpcardiol.2024.102411","article-title":"Unraveling the complex pathophysiology of heart failure: Insights into the role of renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system (SNS).","volume":"49","author":"Maryam","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"R3-20260916","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jchf.2014.09.003","article-title":"Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure.","volume":"3","author":"Mentz","year":"2015","journal-title":"JACC Heart Fail"},{"key":"R4-20260916","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/2251142b0","article-title":"Some properties of angiotensin converting enzyme in the lung in vivo.","volume":"225","author":"Ng","year":"1970","journal-title":"Nature"},{"key":"R5-20260916","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1042\/bj1200221","article-title":"Metabolism of angiotensin I in the pulmonary circulation.","volume":"120","author":"Ryan","year":"1970","journal-title":"Biochem J"},{"key":"R6-20260916","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.jtcvs.2021.02.097","article-title":"Evaluating the evidence for angiotensin II for the treatment of vasoplegia in critically ill cardiothoracic surgery patients.","volume":"163","author":"Chow","year":"2022","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R7-20260916","doi-asserted-by":"crossref","first-page":"2050312120935466","DOI":"10.1177\/2050312120935466","article-title":"Vasoplegia after cardiopulmonary bypass: A narrative review of pathophysiology and emerging targeted therapies.","volume":"8","author":"Barnes","year":"2020","journal-title":"SAGE Open Med"},{"key":"R8-20260916","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1053\/j.jvca.2017.10.032","article-title":"Vasoplegia after cardiovascular procedures-pathophysiology and targeted therapy.","volume":"32","author":"Shaefi","year":"2018","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R9-20260916","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1056\/NEJMra002709","article-title":"The pathogenesis of vasodilatory shock.","volume":"345","author":"Landry","year":"2001","journal-title":"N Engl J Med"},{"key":"R10-20260916","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1056\/NEJMoa1704154","article-title":"Angiotensin II for the treatment of vasodilatory shock.","volume":"377","author":"Khanna","year":"2017","journal-title":"N Engl J Med"},{"key":"R11-20260916","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.jvca.2020.08.001","article-title":"Treatment with angiotensin II is associated with rapid blood pressure response and vasopressor sparing in patients with vasoplegia after cardiac surgery: A post-hoc analysis of Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) study.","volume":"35","author":"Klijian","year":"2021","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R12-20260916","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/978-1-4939-6625-7_7","article-title":"Measurement of angiotensin peptides: HPLC-RIA.","volume":"1527","author":"Brosnihan","year":"2017","journal-title":"Methods Mol Biol"},{"key":"R13-20260916","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13054-023-04322-y","article-title":"An updated \u201cnorepinephrine equivalent\u201d score in intensive care as a marker of shock severity.","volume":"27","author":"Kotani","year":"2023","journal-title":"Crit Care"},{"key":"R14-20260916","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1053\/j.jvca.2019.03.004","article-title":"Synthetic human angiotensin II for postcardiopulmonary bypass vasoplegic shock.","volume":"33","author":"Wieruszewski","year":"2019","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R15-20260916","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.athoracsur.2018.11.047","article-title":"Use of angiotensin II for post cardiopulmonary bypass vasoplegic syndrome.","volume":"108","author":"Evans","year":"2019","journal-title":"Ann Thorac Surg"},{"key":"R16-20260916","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1053\/j.jvca.2020.07.087","article-title":"Angiotensin II for critically ill patients with shock after heart transplant.","volume":"35","author":"Cutler","year":"2021","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R17-20260916","doi-asserted-by":"crossref","first-page":"98","DOI":"10.14797\/mdcvj.576","article-title":"Angiotensin II: A multimodal approach to vasoplegia in a cardiac setting.","volume":"17","author":"Sovic","year":"2021","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"R18-20260916","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/anae.15802","article-title":"A double-blind randomised feasibility trial of angiotensin-2 in cardiac surgery.","volume":"77","author":"Coulson","year":"2022","journal-title":"Anaesthesia"},{"key":"R19-20260916","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1213\/ANE.0000000000006839","article-title":"A pilot study of renin-guided angiotensin-II infusion to reduce kidney stress after cardiac surgery.","volume":"139","author":"Sadjadi","year":"2024","journal-title":"Anesth Analg"},{"key":"R20-20260916","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1213\/ANE.0000000000007779","article-title":"The Renin\u2013angiotensin\u2013aldosterone system in cardiac surgery and angiotensin II therapy for vasoplegia.","volume":"142","author":"Zarbock","year":"2025","journal-title":"Anesth Analg"},{"key":"R21-20260916","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1177\/08850666221145864","article-title":"Angiotensin ii for vasodilatory hypotension in patients requiring mechanical circulatory support.","volume":"38","author":"Wieruszewski","year":"2023","journal-title":"J Intensive Care Med"}],"container-title":["ASAIO Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MAT.0000000000002854","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:00:24Z","timestamp":1789592424000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MAT.0000000000002854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":21,"URL":"https:\/\/doi.org\/10.1097\/mat.0000000000002854","relation":{},"ISSN":["1058-2916","1538-943X"],"issn-type":[{"value":"1058-2916","type":"print"},{"value":"1538-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]}}}